Published in Integr Blood Press Control on May 10, 2010
Which thiazide to choose as add-on therapy for hypertension? Integr Blood Press Control (2014) 0.75
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet (1990) 24.72
Treatment of hypertension in patients 80 years of age or older. N Engl J Med (2008) 21.04
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med (2000) 19.56
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet (2001) 17.97
Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med (1990) 17.52
Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension (2006) 11.68
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med (2008) 11.61
Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation (2000) 6.13
Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol (2003) 6.04
Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet (2009) 5.84
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87
Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med (2007) 4.20
Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension (2007) 2.37
External validity of clinical trials in acute myocardial infarction. Arch Intern Med (2007) 2.14
Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. Diabetes Care (2009) 1.89
A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med (2003) 1.83
Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur Heart J (2003) 1.82
Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J (2009) 1.79
Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med (2007) 1.69
Endothelial function. From vascular biology to clinical applications. Am J Cardiol (2002) 1.63
Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia (2009) 1.59
Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs (2002) 1.41
Blood pressure in Spain: distribution, awareness, control, and benefits of a reduction in average pressure. Hypertension (1998) 1.23
The role of non-haemodynamic factors of the genesis of LVH. Nephrol Dial Transplant (2005) 1.00
Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER. Hypertension (2003) 0.98
Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet (2002) 0.98
Normal systolic blood pressure and risk of heart failure in US male physicians. Eur J Heart Fail (2009) 0.98
Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens (2004) 0.96
[Cardiovascular risk profile of uncontrolled hypertensive patients. The Control-Project study]. Med Clin (Barc) (2007) 0.96
Hypertension in high-risk patients: beware of the underuse of effective combination therapy (results of the PRATIK study). J Hypertens (2002) 0.93
Perindopril/indapamide combination more effective than enalapril in reducing blood pressure and left ventricular mass: the PICXEL study. J Hypertens (2005) 0.90
Mortality attributable to cardiovascular risk factors in Spain. Eur J Clin Nutr (2003) 0.87
Evolution of blood pressure control in Spain. J Hypertens (2007) 0.86
Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study. J Hum Hypertens (2007) 0.85
Blood pressure and lipid goal attainment in the hypertensive population in the primary care setting in Spain. J Clin Hypertens (Greenwich) (2007) 0.84
Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence. J Hypertens Suppl (2008) 0.82
Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. J Renin Angiotensin Aldosterone Syst (2002) 0.82
The ADVANCE trial: clarifying the role of perindopril/indapamide fixed-dose combination in the reduction of cardiovascular and renal events in patients with diabetes mellitus. Am J Cardiovasc Drugs (2009) 0.81
Pharmacokinetics of sustained and immediate release formulations of indapamide after single and repeated oral administration in healthy volunteers. Fundam Clin Pharmacol (2000) 0.81
Blood pressure normalization by fixed perindopril/indapamide combination in hypertensive patients with or without associate metabolic syndrome: results of the OPTIMAX 2 study. Vasc Health Risk Manag (2008) 0.79
Perindopril-based blood pressure lowering reduces major vascular events in Asian and Western participants with cerebrovascular disease: the PROGRESS trial. J Hypertens (2010) 0.79
Indapamide sustained release: a review of its use in the treatment of hypertension. Drugs (2006) 0.79
Large and small artery endothelial function in patients with essential hypertension--effect of ACE inhibition and beta-blockade. Blood Press (2007) 0.79
Perindopril/indapamide 2/0.625 mg/day: a review of its place in the management of hypertension. Drugs (2001) 0.79
Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease. Expert Rev Cardiovasc Ther (2009) 0.79
A systematic review and meta-analysis of the efficacy and safety of a fixed, low-dose perindopril-indapamide combination as first-line treatment of hypertension. Clin Ther (2004) 0.78
Ambulatory blood pressure in hypertensive patients with left ventricular hypertrophy: efficacy of first-line combination perindopril/indapamide therapy. Vasc Health Risk Manag (2007) 0.78
Low-dose fixed combination of perindopril plus indapamide in the diabetic hypertensive population. Expert Rev Cardiovasc Ther (2008) 0.77
A review of Perindopril in the reduction of cardiovascular events. Vasc Health Risk Manag (2006) 0.77
Angiotensin II: an amplifier of cardiovascular risk. Curr Hypertens Rep (2004) 0.77
Application in the STRATHE trial of a score system to compare the efficacy and the tolerability of different therapeutic strategies in the management of hypertension. Vasc Health Risk Manag (2008) 0.76
Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with the metabolic syndrome: data from the SARA Study. J Clin Hypertens (Greenwich) (2008) 0.76
Efficacy of a very-low-dose combination of perindopril and indapamide--preterax compared with cilazapril monotherapy in patients with inadequate blood pressure control--a randomized, double-blind, add-on study. J Chin Med Assoc (2008) 0.75
[Thromboembolic events in patients after a negative computed tomography pulmonary angiogram: A retrospective study of 165 patients]. Arch Bronconeumol (2006) 2.64
Treatment and blood pressure control in Spain during 2002-2010. J Hypertens (2012) 2.13
New evidence, new controversies: a critical review of the European Society of Cardiology 2010 clinical practice guidelines on atrial fibrillation. Rev Esp Cardiol (Engl Ed) (2011) 2.01
Short-term clinical outcome after acute symptomatic pulmonary embolism. Thromb Haemost (2008) 1.54
Patients with atrial fibrillation in a primary care setting: Val-FAAP study. Rev Esp Cardiol (Engl Ed) (2011) 1.46
Importance of electrocardiographic left ventricular hypertrophy in blood pressure control. J Hypertens (2011) 1.39
When office blood pressure measurement is not enough. Int J Cardiol (2009) 1.39
[Ventricular tachycardia in a patient with spongiform myocardiopathy]. Med Clin (Barc) (2004) 1.39
Have we attained the right control of hypertension? Consequences of the 2013 European Society of Hypertension/European Society of Cardiology and Eighth Joint National Committee recommendations. J Hypertens (2014) 1.39
Blood pressure control in hypertensive women aged 65 years or older in a primary care setting. MERICAP study. Rev Esp Cardiol (2011) 1.38
Hypertension and children: should we be aware? Hypertension (2013) 1.10
Prevalence of the metabolic syndrome in patients with hypertension treated in general practice in Spain: an assessment of blood pressure and low-density lipoprotein cholesterol control and accuracy of diagnosis. J Cardiometab Syndr (2007) 0.99
Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig (2009) 0.99
The role of angiotensin receptor blockers and/or angiotensin converting enzyme inhibitors in the prevention of atrial fibrillation in patients with cardiovascular diseases: meta-analysis of randomized controlled clinical trials. Pacing Clin Electrophysiol (2004) 0.97
Obesity, blood pressure, and cardiovascular outcomes. Lancet (2013) 0.89
Diagnosis of elderly patients with heart failure. Eur J Heart Fail (2012) 0.88
Association of anaemia and mortality in patients with acute pulmonary embolism. Thromb Haemost (2009) 0.86
Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in daily clinical practice: the SARA study. J Hypertens (2007) 0.85
[Prognostic value of transthoracic echocardiography in hemodynamically stable patients with acute symptomatic pulmonary embolism]. Arch Bronconeumol (2007) 0.85
Fixed combinations in the management of hypertension: perspectives on lercanidipine-enalapril. Vasc Health Risk Manag (2008) 0.84
Blood pressure and lipid goal attainment in the hypertensive population in the primary care setting in Spain. J Clin Hypertens (Greenwich) (2007) 0.84
Prognostic significance of delays in diagnosis of pulmonary embolism. Thromb Res (2007) 0.83
Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA. Expert Rev Cardiovasc Ther (2009) 0.83
Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study. Cardiovasc Ther (2008) 0.83
Prevalence of left ventricular hypertrophy detected by Cornell voltage-duration product in a hypertensive population. Blood Press (2008) 0.81
Detection of left ventricular hypertrophy by different electrocardiographic criteria in clinical practice. Findings from the Sara study. Clin Exp Hypertens (2010) 0.80
Sex differences in the hypertensive population with chronic ischemic heart disease. J Clin Hypertens (Greenwich) (2008) 0.80
High heart rate: more than a risk factor. Lessons from a clinical practice survey. Int J Cardiol (2008) 0.79
Diagnosis of heart failure in elderly patients: a clinical challenge. Eur J Heart Fail (2011) 0.79
Clinical profile and management of patients with hypertension and chronic ischemic heart disease according to BMI. Obesity (Silver Spring) (2010) 0.79
[Anti-factor Xa activity of enoxaparin for thromboprophylaxis in nonsurgical patients is dependent on body mass]. Arch Bronconeumol (2008) 0.79
Olmesartan medoxomil plus hydrochlorothiazide for treating hypertension. Expert Opin Pharmacother (2008) 0.79
New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. Expert Opin Pharmacother (2012) 0.79
[Incidence of symptomatic and asymptomatic chronic thromboembolic pulmonary hypertension]. Arch Bronconeumol (2010) 0.78
Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study. J Renin Angiotensin Aldosterone Syst (2006) 0.78
Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: results of the irbesartan-amiodarone trial. Card Electrophysiol Rev (2003) 0.78
SEAIC-SEORL. Consensus Document on Nasal Polyposis. POLINA Project. J Investig Allergol Clin Immunol (2011) 0.78
Valsartan-amlodipine-hydrochlorothiazide: the definitive fixed combination? Expert Rev Cardiovasc Ther (2010) 0.78
Rosuvastatin and cardiovascular continuum when time is important. J Am Coll Cardiol (2010) 0.78
Azilsartan medoxomil in the treatment of hypertension: the definitive angiotensin receptor blocker? Expert Opin Pharmacother (2013) 0.78
Detection of unrecognized clinical heart failure in elderly hypertensive women attended in primary care setting. Blood Press (2010) 0.77
Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications. Expert Rev Cardiovasc Ther (2013) 0.77
Concomitance of cardiovascular comorbidities in the hypertensive population: not only in the United States. Arch Intern Med (2008) 0.77
Gender differences in the diagnosis and treatment of left ventricular hypertrophy detected by different electrocardiographic criteria. Findings from the SARA study. Heart Vessels (2010) 0.77
Low-dose fixed combination of perindopril plus indapamide in the diabetic hypertensive population. Expert Rev Cardiovasc Ther (2008) 0.77
Variables associated with change in blood pressure control status after 1-year follow up in primary care: a retrospective analysis: the TAPAS study. Eur J Prev Cardiol (2013) 0.77
High resting heart rate: a cardiovascular risk factor or a marker of risk? Eur Heart J (2008) 0.77
Antihypertensive and organ-protective effects of benazepril. Expert Rev Cardiovasc Ther (2010) 0.76
Clinical profile and management of patients with chronic ischemic heart disease according to age in the population daily attended by cardiologists in Spain The ELDERCIC study. Eur J Intern Med (2010) 0.76
Candesartan in the treatment of hypertension: what have we learnt in the last decade? Expert Opin Drug Saf (2011) 0.76
[Adequacy of the treatment of hypertensive patients with metabolic syndrome]. Med Clin (Barc) (2007) 0.76
Clinical profile and management of hypertensive patients with chronic ischemic heart disease and renal dysfunction attended by cardiologists in daily clinical practice. J Hypertens (2008) 0.76
Electrocardiographic left ventricular hypertrophy regression induced by an angiotensin receptor blocker-based regimen in hypertensive patients with diabetes: data from the SARA study. J Renin Angiotensin Aldosterone Syst (2009) 0.76
Prevalence of renal dysfunction according to the type of atrial fibrillation and anticoagulation treatment in patients who attended primary care in Spain. Future Cardiol (2014) 0.76
Renal insufficiency should be included in stroke risk scores. Kidney Int (2013) 0.76
Arrhythmogenic right ventricular dysplasia. J Am Coll Cardiol (2009) 0.75
Angiotensin-receptor blockade, cancer, and concerns. Lancet Oncol (2010) 0.75
Blood pressure goal achievement with olmesartan medoxomil-based treatment: additional analysis of the OLMEBEST study. Vasc Health Risk Manag (2009) 0.75
Clinical implications of different biomarkers in elderly patients with heart failure. Biomark Med (2014) 0.75
Treating heart rate for the prevention of diabetes: the next step? Am J Hypertens (2009) 0.75
Diuretic strategies in patients with acute heart failure. N Engl J Med (2011) 0.75
Letter by Barrios et al regarding article, "Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women". Circulation (2010) 0.75
Ischemic heart disease and women: more answers are needed. Rev Esp Cardiol (Engl Ed) (2012) 0.75
[Atrial fibrillation in clinical practice: more answers are required]. Med Clin (Barc) (2013) 0.75
High heart rate: more data for a question unresolved. Am J Cardiol (2009) 0.75
Regression of left ventricular hypertrophy in diabetics by a candesartan-based regimen in clinical practice. Diabetes Res Clin Pract (2007) 0.75
Cardiovascular protection with candesartan in patients with metabolic disorders. Hypertens Res (2010) 0.75
Antihypertensive drugs in daily clinical practice: are there differences between genders? Eur Heart J (2009) 0.75
Importance of blood pressure control in hypertensive patients with coronary heart disease in clinical practice to reduce the risk of stroke. Stroke (2009) 0.75
Gender differences in left ventricular hypertrophy regression. Hypertension (2008) 0.75
Atrial fibrillation and atherothrombosis: the importance of anticoagulation. Am Heart J (2009) 0.75
Women and coronary heart disease: improving step by step. Am Heart J (2008) 0.75
Coronary flow reserve: a new target for treating hypertension. Hypertens Res (2009) 0.75
Letter by barrios et Al regarding article, "heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial". Circulation (2009) 0.75
[Comments on the ESC/EAS guidelines for the management of dyslipidaemias 2011. A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology]. Rev Esp Cardiol (2011) 0.75
Renal function and coronary disease: not only in clinical trials. Int J Cardiol (2009) 0.75
N-acetylcysteine for the prevention of atrial fibrillation: beyond its antioxidant effect. Eur Heart J (2008) 0.75
Globalization of blood pressure control. Arch Intern Med (2009) 0.75
Hypertension and women: a worldwide project. Am J Med (2009) 0.75
Reply to f. Catalá-López et al. J Hypertens (2013) 0.75
Importance of perception for blood pressure control. Arch Intern Med (2008) 0.75
Combined therapy in the treatment of hypertension: but which? J Hypertens (2009) 0.75
Anticoagulation in non-valvular atrial fibrillation: underused or wrongly used? Am J Cardiol (2011) 0.75
Resistant hypertension. What is the best approach? Rev Esp Cardiol (2009) 0.75
Aliskiren in the management of hypertension. Am J Cardiovasc Drugs (2010) 0.75
Gender and blood pressure control. Hypertension (2008) 0.75
Importance of identifying renal disease early. Rev Esp Cardiol (2010) 0.75
Doxazosin and heart failure: to be or not to be. J Hypertens (2009) 0.75
[Lesions produced by radiofrequency ablation of the cavotricuspid isthmus in an experimental model]. Rev Esp Cardiol (2003) 0.75
Hypertension, has treatment à la Carte arrived? Can J Cardiol (2011) 0.75
Are general blood pressure targets still valid? Hellenic J Cardiol (2011) 0.75
New data on ONTARGET: more confusion? J Clin Hypertens (Greenwich) (2010) 0.75
Clinical applicability of B-type natriuretic peptide in patients with suspected heart failure in primary care in Spain: the PANAMA study. Expert Rev Cardiovasc Ther (2011) 0.75
[Can the nephroprotective effect of N-acetylcysteine be optimized?]. Rev Esp Cardiol (2010) 0.75
[What has been done? What to do for better results of hypertension in Spain?]. Med Clin (Barc) (2009) 0.75
Aliskiren: a new drug for an old problem. Cardiovasc Hematol Agents Med Chem (2010) 0.75
Blood pressure goals revisited. J Hypertens (2016) 0.75
Beating the clock: reducing cardiovascular risk by rapid blood pressure reduction with olmesartan. Expert Opin Pharmacother (2010) 0.75